Michael Arad

List of Publications by Year in Descending Order

79 papers	3,391 citations	26 h-index	57 g-index
86 ext. papers	4,321 ext. citations	6.7 avg, IF	4.78 L-index

#	Paper	IF	Citations
79	The Late Effects of Pregnancy on Aortic Dimensions in Patients with Marfan Syndrome. *Cardiology*, **2021**, 146, 98-105	1.6	1
78	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2021**, 42, 1554-1568	9.5	88
77	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *European Journal of Heart Failure*, **2021**, 23, 512-526	12.3	35
76	Multi-system neurological disorder associated with a CRYAB variant. *Neurogenetics*, **2021**, 22, 117-125	3	
75	Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system. *Cardiovascular Diabetology*, **2021**, 20, 90	8.7	9
74	Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study. *Targeted Oncology*, **2021**, 16, 471-483	5	5
73	Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy. *European Journal of Heart Failure*, **2021**, 23, 1276-1286	12.3	7
72	Depressed adrenergic inotropic responsiveness and intracellular calcium handling abnormalities in Duchenne Muscular Dystrophy patientsTinduced pluripotent stem cell-derived cardiomyocytes. *Journal of Cellular and Molecular Medicine*, **2021**, 25, 3922-3934	5.6	3
71	Investigating -Related Dilated Cardiomyopathy Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
70	Cardiomyopathy: Consequences of Impaired Autophagy in the Heart. *Journal of the American Heart Association*, **2021**, 10, e018829	6	2
69	Anesthesia in Parturients Presenting with Marfan Syndrome. *Israel Medical Association Journal*, **2021**, 23, 437-440	0.9	
68	Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European Registry. *Circulation Genomic and Precision Medicine*, **2020**, 13, e003117	5.2	10
67	Donor thyroid hormone therapy is associated with an increased risk of graft dysfunction after heart transplantation. *Clinical Transplantation*, **2020**, 34, e13887	3.8	4
66	Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway. *Prostaglandins and Other Lipid Mediators*, **2020**, 150, 106454	3.7	4
65	Reduction in Filamin C transcript is associated with arrhythmogenic cardiomyopathy in Ashkenazi Jews. *International Journal of Cardiology*, **2020**, 317, 133-138	3.2	3
64	Sex Differences in Clinical Characteristics and 1- and 10-Year Mortality Among Patients Hospitalized With Acute Heart Failure. *American Journal of the Medical Sciences*, **2020**, 360, 392-401	2.2	1
63	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. *Journal of the American College of Cardiology*, **2020**, 76, 186-197	15.1	16

62	The Peroxisome Proliferator-Activated Receptor-Gamma Coactivator-1α–Heme Oxygenase 1 Axis, a Powerful Antioxidative Pathway with Potential to Attenuate Diabetic Cardiomyopathy. *Antioxidants and Redox Signaling*, **2020**, 32, 1273-1290	8.4	6
61	New Insights on Genetic Diagnostics in Cardiomyopathy and Arrhythmia Patients Gained by Stepwise Exome Data Analysis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
60	Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutants. *Journal of Muscle Research and Cell Motility*, **2020**, 41, 251-258	3.5	2
59	Sex-Based Differences in Characteristics and In-Hospital Outcomes among Patients With Diagnosed Acute Myocarditis. *American Journal of Cardiology*, **2020**, 125, 1694-1699	3	3
58	Differences in Mortality of New-Onset (De-Novo) Acute Heart Failure Versus Acute Decompensated Chronic Heart Failure. *American Journal of Cardiology*, **2019**, 124, 554-559	3	15
57	Efficacy and safety of exercise rehabilitation in patients with hypertrophic cardiomyopathy. *Journal of Cardiology*, **2019**, 74, 466-472	3	4
56	The Role of Heme Oxygenase 1 in the Protective Effect of Caloric Restriction against Diabetic Cardiomyopathy. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	15
55	Response by Naftali-Shani et al to Letter Regarding Article, "Modeling Peripartum Cardiomyopathy With Human Induced Pluripotent Stem Cells Reveals Distinctive Abnormal Function of Cardiomyocytes". *Circulation*, **2019**, 139, e992-e993	16.7	
54	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*, **2019**, 21, 553-576	12.3	118
53	The Hyperpolarization-Activated Cyclic-Nucleotide-Gated Channel Blocker Ivabradine Does Not Prevent Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia. *Frontiers in Pharmacology*, **2019**, 10, 1566	5.6	4
52	Electrophysiological abnormalities in induced pluripotent stem cell-derived cardiomyocytes generated from Duchenne muscular dystrophy patients. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 2125-2135	5.6	23
51	The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy. *European Heart Journal*, **2019**, 40, 1671-1677	9.5	15
50	The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts. *Molecular Genetics and Metabolism*, **2019**, 126, 224-235	3.7	33
49	Generation of Duchenne muscular dystrophy patient-specific induced pluripotent stem cell line lacking exons 45-50 of the dystrophin gene (IITi001-A). *Stem Cell Research*, **2018**, 29, 111-114	1.6	7
48	CRISPR correction of the PRKAG2 gene mutation in the patient's induced pluripotent stem cell-derived cardiomyocytes eliminates electrophysiological and structural abnormalities. *Heart Rhythm*, **2018**, 15, 267-276	6.7	40
47	Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α'. *Cardiovascular Diabetology*, **2018**, 17, 111	8.7	82
46	European expert consensus statement on therapeutic goals in Fabry disease. *Molecular Genetics and Metabolism*, **2018**, 124, 189-203	3.7	71
45	De novo mitral regurgitation as a cause of heart failure exacerbation in patients with hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2018**, 252, 122-127	3.2	3

44	Peptide-based development of PKA activators. *New Journal of Chemistry*, **2018**, 42, 18585-18597	3.6	1
43	Modeling Peripartum Cardiomyopathy With Human Induced Pluripotent Stem Cells Reveals Distinctive Abnormal Function of Cardiomyocytes. *Circulation*, **2018**, 138, 2721-2723	16.7	5
42	PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1 axis. *Experimental Cell Research*, **2018**, 373, 112-118	4.2	31
41	Functional abnormalities in induced Pluripotent Stem Cell-derived cardiomyocytes generated from titin-mutated patients with dilated cardiomyopathy. *PLoS ONE*, **2018**, 13, e0205719	3.7	24
40	Sub-acute vs. Late-onset Presentation of Oncotherapy Related Cardiotoxicity: Predictors of Cardiac Function Recovery and Long-Term Outcome. *Israel Medical Association Journal*, **2018**, 20, 486-490	0.9	
39	Blood pressure dynamics during exercise rehabilitation in heart failure patients. *European Journal of Preventive Cardiology*, **2017**, 24, 818-824	3.9	1
38	Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene mutation). *American Journal of Medical Genetics, Part A*, **2017**, 173, 2461-2466	2.5	15
37	SK4 K channels are therapeutic targets for the treatment of cardiac arrhythmias. *EMBO Molecular Medicine*, **2017**, 9, 415-429	12	24
36	Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models. *Heart Rhythm*, **2017**, 14, 1053-1060	6.7	18
35	Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up. *Clinical Transplantation*, **2017**, 31, e13133	3.8	22
34	Metformin therapy reduces the risk of malignancy after heart transplantation. *Journal of Heart and Lung Transplantation*, **2017**, 36, 1350-1357	5.8	7
33	Risk of early, intermediate, and late rejection following heart transplantation: Trends over the past 25 years and relation to changes in medical management. Tertiary center experience: The Sheba Heart Transplantation Registry. *Clinical Transplantation*, **2017**, 31, e13063	3.8	6
32	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. *European Heart Journal*, **2017**, 38, 2649-2662	9.5	88
31	Caloric restriction ameliorates cardiomyopathy in animal model of diabetes. *Experimental Cell Research*, **2017**, 350, 147-153	4.2	17
30	The role of 20-HETE in cardiovascular diseases and its risk factors. *Prostaglandins and Other Lipid Mediators*, **2016**, 125, 108-17	3.7	47
29	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. *Journal of the American College of Cardiology*, **2016**, 68, 2440-2451	15.1	213
28	Angiogenic Imbalance and Residual Myocardial Injury in Recovered Peripartum Cardiomyopathy Patients. *Circulation: Heart Failure*, **2016**, 9,	7.6	24
27	Clinical Experience With Deferiprone Treatment for Friedreich Ataxia. *Journal of Child Neurology*, **2016**, 31, 1036-40	2.5	33

26	Epoxyeicosatrienoic Acids Regulate Adipocyte Differentiation of Mouse 3T3 Cells, Via PGC-1 Activation, Which Is Required for HO-1 Expression and Increased Mitochondrial Function. *Stem Cells and Development*, **2016**, 25, 1084-94	4.4	53
25	Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center. *European Journal of Preventive Cardiology*, **2015**, 22, 13-9	3.9	46
24	Ethnic differences among implantable cardioverter defibrillators recipients in Israel. *American Journal of Cardiology*, **2015**, 115, 1102-6	3	3
23	Inherited cardiomyopathies--Novel therapies. *Pharmacology & Therapeutics*, **2015**, 155, 36-48	13.9	13
22	Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations. *Journal of Cellular and Molecular Medicine*, **2015**, 19, 2006-18	5.6	56
21	TLR4 Expression Is Associated with Left Ventricular Dysfunction in Patients Undergoing Coronary Artery Bypass Surgery. *PLoS ONE*, **2015**, 10, e0120175	3.7	19
20	Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis. *BioMed Research International*, **2015**, 2015, 590851	3	6
19	Phenotype and prognostic correlations of the converter region mutations affecting the myosin heavy chain. *Heart*, **2015**, 101, 1047-53	5.1	34
18	Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice. *Heart Rhythm*, **2014**, 11, 1471-9	6.7	16
17	Merits and pitfalls of genetic testing in a hypertrophic cardiomyopathy clinic. *Israel Medical Association Journal*, **2014**, 16, 707-13	0.9	4
16	A family with recurrent sudden death and no clinical clue. *Annals of Noninvasive Electrocardiology*, **2012**, 17, 387-93	1.5	7
15	Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. *Heart Rhythm*, **2011**, 8, 1546-52	6.7	17
14	Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice. *Heart Rhythm*, **2010**, 7, 1676-82	6.7	36
13	Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. *JAMA - Journal of the American Medical Association*, **2009**, 301, 1253-9	27.4	240
12	Exercise training in advanced heart failure patients: discordance between improved exercise tolerance and unchanged NT-proBNP levels. *International Journal of Cardiology*, **2008**, 126, 114-9	3.2	16
11	Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. *Circulation*, **2008**, 117, 144-54	16.7	63
10	AMP-activated protein kinase in the heart: role during health and disease. *Circulation Research*, **2007**, 100, 474-88	15.7	269
9	Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. *Journal of Clinical Investigation*, **2007**, 117, 1432-9	15.9	81

8	Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. *Journal of Clinical Investigation*, **2007**, 117, 1814-23	15.9	127
7	Glycogen storage diseases presenting as hypertrophic cardiomyopathy. *New England Journal of Medicine*, **2005**, 352, 362-72	59.2	473
6	Genetic ideology of dilated cardiompathy. *Israel Medical Association Journal*, **2005**, 7, 392-6	0.9	2
5	Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. *Journal of Clinical Investigation*, **2002**, 109, 357-362	15.9	341
4	Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. *Journal of Clinical Investigation*, **2002**, 109, 357-62	15.9	151
3	Limb ischemia preconditions the heart against reperfusion tachyarrhythmia. *American Journal of Physiology - Heart and Circulatory Physiology*, **1997**, 273, H1707-12	5.2	66
2	Prostaglandins and the antiarrhythmic effect of preconditioning in the isolated rat heart. *Molecular and Cellular Biochemistry*, **1996**, 160-161, 249-55	4.2	11
1	Effects of Heat-Exercise Stress, NBC Clothing, and Pyridostigmine Treatment on Psychomotor and Subjective Measures of Performance. *Military Medicine*, **1992**, 157, 210-214	1.3	14